Nivix Pharmaceuticals Calls General Meeting, Key Agenda is IPO Issuance
Nivix Pharmaceuticals IPO General
12th December 2025, Kathmandu
Nivix Pharmaceuticals IPO General Meeting has been officially scheduled. The company is actively moving forward with its plan to issue Initial Public Offerings (IPO) to the general public.
Nivix Pharmaceuticals IPO General
This crucial proposal will form the central part of the upcoming Nivix Pharmaceuticals IPO General Meeting.
The Ordinary General Meeting (OGM) is set for Poush 18. This date corresponds to January 1, 2026. The company’s Board of Directors finalized this decision.
They met on Mangsir 25 (December 11, 2025). This action marks a key progression in the company’s corporate and financial strategy.
General Meeting Venue and Core Proposals
The OGM will take place in Pokhara. The specific location is the Pokhara Event Center. Shareholders will review and vote on several important corporate matters.
The agenda includes four regular proposals and three special resolutions. The most critical item is a special resolution concerning the IPO process. It aims to grant necessary authority to the Board of Directors.
This power allows the board to proceed with all remaining steps for the IPO issuance. This delegation of authority will help fast-track the listing process.
Strategy: Leveraging IPO for Business Growth
Nivix Pharmaceuticals Limited has outlined clear objectives for its public offering. The capital raised from the IPO will be used for strategic investments. The primary focus is on two key areas: business expansion and institutional strengthening. This strategy supports long-term, sustainable growth.
Advertisement
The company operates a production factory in Tanahun. Management views the IPO as a vital mechanism. It will help expand operational capacity and enhance market reach.
Transitioning to a public limited company structure is also expected to increase transparency. It will further strengthen corporate governance standards. This attracts investor confidence and broader stakeholder trust.
The Impact on Nepal’s Pharmaceutical and Capital Market
Nepal’s pharmaceutical sector is currently experiencing robust growth. Nivix Pharmaceuticals’ decision to float an IPO highlights this positive industry momentum. It introduces a fresh investment opportunity for the public. Investors are keen to diversify their portfolios into growing sectors.
A successful IPO by Nivix Pharmaceuticals is significant for the entire capital market. It adds essential depth and variety to the available listings. Furthermore, it sets a positive example for other mid-sized enterprises.
They, too, can utilize the public market for essential capital formation. This ultimately stimulates economic activity. The market is waiting for the official prospectus and final issue details. Nivix Pharmaceuticals is positioning itself for a major expansion phase after the IPO.
Recent Regulatory and Corporate Activities
The company has been proactive in its preparations. Its IPO proposal was recently added to the Securities Board of Nepal (SEBON) pipeline. The plan involves issuing 1,375,000 shares at a par value of Rs. 100 per share. This issue aims to raise approximately Rs. 13.75 crore.
The company has already appointed Nepal SBI Merchant Banking Limited as the issue manager. This appointment and the calling of the OGM demonstrate the company’s commitment to timely execution. The Board is actively executing all corporate steps necessary to bring the IPO to market. They are prioritizing efficient compliance with all regulatory requirements.
For more: Nivix Pharmaceuticals IPO General
